Multiple Myeloma Defining Events (SLiM-CRAB Criteria)
Multiple myeloma is diagnosed when there is ≥10% clonal bone marrow plasma cells or biopsy-proven plasmacytoma PLUS at least one myeloma-defining event from either CRAB features or SLiM biomarkers. 1
CRAB Features (End-Organ Damage)
These represent symptomatic disease requiring treatment:
- C (Calcium): Serum calcium >11 mg/dL (>2.75 mmol/L) 1
- R (Renal): Creatinine >2 mg/dL OR creatinine clearance <40 mL/min 1, 2
- A (Anemia): Hemoglobin <10 g/dL OR >2 g/dL below normal 1, 2
- B (Bone): One or more osteolytic lesions on skeletal radiography, whole-body MRI, or whole-body FDG-PET/CT 1, 2
SLiM Biomarkers (High-Risk Features)
These biomarkers predict near-inevitable progression to symptomatic disease and warrant treatment initiation before end-organ damage occurs: 1, 3
- S (Sixty): ≥60% clonal plasma cells in bone marrow 1, 2
- Li (Light chain ratio): Involved/uninvolved serum free light chain ratio ≥100 (with involved FLC ≥100 mg/L) 1, 2
- Critical caveat: Recent data suggests patients with FLC ratio >100 but urinary monoclonal protein <200 mg/24h have only 13.5% risk of symptomatic progression at 2 years, with median time to progression of 7.9 years 4. Exercise caution in this subgroup.
- M (MRI): >1 focal marrow lesion on MRI (each ≥5 mm in size, nonosteolytic) 1, 2
Key Algorithmic Points
The updated 2014 IMWG criteria fundamentally changed MM diagnosis by incorporating SLiM biomarkers alongside traditional CRAB features. 3 This allows treatment initiation before irreversible organ damage occurs in high-risk patients.
All myeloma-defining events together are termed "SLiM-CRAB." 1, 2 Patients meeting any single criterion from either category have active multiple myeloma and should be offered treatment.
Distinguishing from Smoldering Myeloma
Smoldering (asymptomatic) MM is defined as:
- Serum M-protein (IgG or IgA) ≥30 g/L AND/OR
- Clonal bone marrow plasma cells 10-59% AND
- Absence of any CRAB features, SLiM biomarkers, or amyloidosis 1, 2
Imaging Clarifications
The IMWG clarified that bone disease can be diagnosed by skeletal radiography, whole-body MRI, or whole-body FDG-PET/CT—not just conventional X-rays. 1, 5 This increases sensitivity for detecting bone involvement and allows earlier diagnosis.
Common Pitfalls
- Don't wait for CRAB features in patients with SLiM biomarkers—these patients have active MM requiring treatment 1, 3
- For FLC ratio ≥100: Verify involved FLC is ≥100 mg/L AND check 24-hour urine protein; if <200 mg/24h, progression may be slower than expected 4, 6
- MRI focal lesions must be ≥5 mm to qualify as myeloma-defining 5, 7
- Bone marrow plasma cells ≥60% alone may transform more slowly than previously thought in absence of other high-risk features 4